Prelude Capital Management’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-22,100
Closed -$59.9K 1355
2025
Q4
$59.9K Buy
22,100
+5,900
+36% +$19.4K ﹤0.01% 1229
2025
Q3
$68.5K Buy
+16,200
New +$71.2K 0.01% 1087
2025
Q1
Sell
-29,924
Closed -$139K 1317
2024
Q4
$139K Buy
+29,924
New +$164K 0.01% 1060
2024
Q3
Sell
-16,277
Closed -$127K 1379
2024
Q2
$127K Buy
16,277
+3,701
+29% +$27.4K 0.01% 1076
2024
Q1
$89.3K Sell
12,576
-48,021
-79% -$318K ﹤0.01% 1211
2023
Q4
$406K Buy
60,597
+10,413
+21% +$58.6K 0.03% 613
2023
Q3
$283K Buy
50,184
+24,123
+93% +$161K 0.02% 696
2023
Q2
$144K Buy
26,061
+11,705
+82% +$63K 0.01% 889
2023
Q1
$89.7K Sell
14,356
-3,087
-18% -$17.2K 0.01% 961
2022
Q4
$81.3K Buy
+17,443
New +$85.9K ﹤0.01% 1101
2022
Q3
Sell
-23,341
Closed -$138K 1688
2022
Q2
$138K Buy
+23,341
New +$260K ﹤0.01% 1367

Other funds holding GDRX

Prelude Capital Management's GDRX Position: Q1 2026 in Review

Prelude Capital Management sold out of GoodRx Holdings (GDRX) in Q1 2026, closing a stake of 22,100 shares — an estimated $59.9K sold.

Prelude Capital Management first reported a position in GDRX in Q2 2022 and held it in 11 quarters. The position peaked at $406K in Q4 2023. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • Prelude Capital Management reported no remaining GoodRx Holdings position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 22,100 GoodRx Holdings shares in Q1 2026, an estimated $59.9K.
  • Prelude Capital Management first reported a position in GoodRx Holdings in Q2 2022 and held it in 11 quarters.
  • Prelude Capital Management's GoodRx Holdings position peaked at $406K in Q4 2023.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.